XML 44 R29.htm IDEA: XBRL DOCUMENT v3.25.3

Note 11 - Segment Information (Tables)

6 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three months ended September 30, 2025		Sterilization and Disinfection Control				Biopharmaceutical Development				Calibration Solutions				Clinical Genomics				Total
Revenues (a):		$	22,107			$	13,920			$	13,570			$	11,140			$	60,737
Less
Depreciation in cost of revenues			461				66				112				152				791
Amortization in cost of revenues			140				375				-				192				707
Other cost of revenues (b)			6,636				5,350				5,223				4,699				21,908
Total segment cost of revenues			7,237				5,791				5,335				5,043				23,406
Gross Profit (c)		$	14,870			$	8,129			$	8,235			$	6,097			$	37,331
Reconciling items:
Operating expense																		$	32,607
Operating income																			4,724
Nonoperating expense, net																			2,725
Earnings before income taxes																		$	1,999

Three months ended September 30, 2024		Sterilization and Disinfection Control				Biopharmaceutical Development				Calibration Solutions				Clinical Genomics				Total
Revenues (a):		$	22,205			$	11,867			$	12,262			$	11,499			$	57,833
Less
Depreciation in cost of revenues			374				40				207				283				904
Amortization in cost of revenues			134				346				-				192				672
Non-cash GKE inventory step-up amortization			454				-				-				-				454
Other cost of revenues (b)			6,071				4,314				4,845				5,118				20,348
Total segment cost of revenues			7,033				4,700				5,052				5,593				22,378
Gross Profit (c)		$	15,172			$	7,167			$	7,210			$	5,906			$	35,455
Reconciling items:
Operating expense																		$	31,947
Operating income																			3,508
Nonoperating (income), net																			(304	)
Earnings before income taxes																		$	3,812

Six months ended September 30, 2025		Sterilization and Disinfection Control				Biopharmaceutical Development				Calibration Solutions				Clinical Genomics				Total
Revenues (a):		$	47,517			$	25,406			$	25,920			$	21,437			$	120,280
Less
Depreciation in cost of revenues			911				155				217				318				1,601
Amortization in cost of revenues			279				747				-				383				1,409
Other cost of revenues (b)			13,291				10,069				10,426				9,214				43,000
Total segment cost of revenues			14,481				10,971				10,643				9,915				46,010
Gross Profit (c)		$	33,036			$	14,435			$	15,277			$	11,522			$	74,270
Reconciling items:
Operating expense																		$	66,482
Operating income																			7,788
Nonoperating (income), net																			(1,223	)
Earnings before income taxes																		$	9,011

Six months ended September 30, 2024		Sterilization and Disinfection Control				Biopharmaceutical Development				Calibration Solutions				Clinical Genomics				Total
Revenues (a):		$	45,162			$	23,875			$	24,063			$	22,903			$	116,003
Less
Depreciation in cost of revenues			793				86				392				495				1,766
Amortization in cost of revenues			245				691				-				383				1,319
Non-cash GKE inventory step-up amortization			1,232				-				-				-				1,232
Other cost of revenues (b)			12,162				7,972				9,219				9,629				38,982
Total segment cost of revenues			14,432				8,749				9,611				10,507				43,299
Gross Profit (c)		$	30,730			$	15,126			$	14,452			$	12,396			$	72,704
Reconciling items:
Operating expense																		$	63,616
Operating income																			9,088
Nonoperating expense, net																			1,371
Earnings before income taxes																		$	7,717

Schedule of Segment Reporting Information, by Inventory Segment [Table Text Block]

		September 30,				March 31,
		2025				2025
Sterilization and Disinfection Control		$	6,771			$	5,545
Biopharmaceutical Development			5,715				4,934
Calibration Solutions			6,150				5,110
Clinical Genomics			9,103				9,776
Total inventories		$	27,739			$	25,365

X

- Definition

A table disclosing the inventory totals for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment inventory reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment inventory.

+ References

No definition available.

+ Details

Name:	mlab_ScheduleOfSegmentReportingInformationByInventorySegmentTableTextBlock
Namespace Prefix:	mlab_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration